Freeze and fight: new combo tackles early lung cancer without surgery

NCT ID NCT07064876

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This phase II trial tests whether combining cryoablation (freezing the tumor) with the immunotherapy drug serplulimab can treat early-stage non-small cell lung cancer in people who cannot have surgery or radiation. Twenty-five adults with stage Ia NSCLC will receive one cryoablation procedure followed by up to six doses of serplulimab. The study will measure how many patients' tumors shrink or disappear, and track survival and side effects.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
serplulimab (a PD-1 inhibitor immunotherapy) and cryoablation (a procedure that freezes and destroys tumor tissue)
What this could lead to
If it works, this combination could offer a non-surgical treatment option for early-stage lung cancer, potentially controlling the disease and improving survival.
What could go wrong
This is a small, early-phase trial with only 25 participants and no comparison group, so results may not apply broadly. The immunotherapy can cause immune-related side effects, and the freezing procedure carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhongshan Hospital Affiliated to Fudan University, No. 180 Fenglin Road, Xuhui District,

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.